Exciting Developments from BridgeBio Oncology at SABCS
BridgeBio Oncology Therapeutics, Inc. (NASDAQ: BBOT) recently made headlines with its announcement of two significant poster presentations for its innovative treatment, BBO-10203. This groundbreaking compound is designed to target RAS-pathway malignancies, emphasizing the company's commitment to advancing cancer treatment methodologies. The presentations will occur during the renowned San Antonio Breast Cancer Symposium.
Poster Presentation Highlights
This year, the symposium is poised to showcase the potential of BBO-10203, a first-in-class agent designed to break the interaction between RAS and PI3K?. This selective breaker has shown promise in inhibiting tumor growth in breast cancer models. The presentations will take place on key dates during the conference, attracting significant attention from medical professionals and researchers alike.
Late Breaking Pre-clinical Details
The late-breaking pre-clinical poster will delve into BBO-10203's ability to suppress tumor growth when used alone or in conjunction with fulvestrant or ribociclib. Notably, this compound achieves these outcomes without causing hyperglycemia, a common concern with many cancer treatments. It will be presented by Kerstin Sinkevicius, PhD, highlighting the scientific rigor behind the research.
Trials in Progress: BBO-10203 Overview
The second poster will focus on ongoing clinical trials, specifying the BREAKER-101 study. This phase 1a/1b open-label study explores the safety, tolerability, and efficacy of BBO-10203. The findings aim to clarify the drug's potential applications for patients grappling with advanced solid tumors, enriching the existing cancer treatment landscape.
Understanding BBO-10203
BBO-10203 stands out as an orally bioavailable small molecule that effectively targets RAS-driven PI3K?-AKT signaling within tumors. Given that it can operate independently of the mutational status of RAS or PI3K?, it provides a versatile tool for addressing tumors associated with mutations in these critical oncogenes. Current evaluations in the Phase 1 BREAKER-101 trial are focusing on patients with HER2+ amplified or HR+/HER2- breast cancer, as well as those with KRAS mutant colorectal or non-small cell lung cancer.
About BridgeBio Oncology Therapeutics
BridgeBio Oncology is recognized as a clinical-stage biopharmaceutical entity devoted to crafting advanced therapies focusing on RAS and PI3K? malignancies. Their mission emphasizes improving therapeutic outcomes for patients whose conditions are driven by these prevalent oncogenes. The innovative pipeline is a testament to their proactive approach to cancer therapy, making strides where other methods have fallen short.
BBOT Contacts
For inquiries related to investments, Heather Armstrong serves as the Head of Investor Relations at BridgeBio Oncology. Interested individuals may connect via Investors@BBOTx.com. Additionally, media contacts include Jake Robison from Inizio Evoke Comms, reachable through Jake.robison@inizioevoke.com for further information or interviews.
Frequently Asked Questions
What is BBO-10203?
BBO-10203 is an orally bioavailable small molecule that inhibits the interaction between RAS and PI3K?, targeting RAS-driventh tumors.
What are the key presentations about at SABCS?
The presentations focus on BBO-10203's efficacy in inhibiting tumor growth and its safety in combination treatments.
Who are the presenters for the poster sessions?
Kerstin Sinkevicius, PhD, and Andreas Varkaris, MD, PhD, will present their findings at the symposium.
What types of cancer is BBO-10203 targeting?
BBO-10203 is targeting HER2+ amplified or HR+/HER2- breast cancer, as well as colorectal and non-small cell lung cancers with KRAS mutations.
How can I contact BridgeBio for more information?
Contact Investor Relations at Investors@BBOTx.com or the media through Jake.robison@inizioevoke.com for further inquiries.
